Drug intelligence / Profile preview

NL-201 + pembrolizumab

Development stage: Discontinued
Lead developer: Neurogene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

NL-201 + pembrolizumab is an investigational combination therapy being evaluated for advanced, relapsed, or refractory solid tumors. NL-201 is a de novo protein immunotherapy designed to agonize the interleukin-2 receptor beta-gamma (IL-2Rβγ) and interleukin-15 receptor (IL-15R), expanding CD8+ T cells and NK cells with minimal activity on regulatory T cells. Pembrolizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as a checkpoint inhibitor to enhance immune response against tumors. This combination aims to synergize the immune-stimulatory effects of NL-201 with the immune checkpoint blockade of pembrolizumab to enhance antitumor activity[3][5][6][7].

Other names: NL-201 and pembrolizumabNL201 and pembrolizumabNL 201 and pembrolizumab

Targets

IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on NL-201 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NL-201 + pembrolizumab.

Explore the full profile